Abstract Number: 1851 • ACR Convergence 2020
Different Disease Activity Trajectories in Early Axial Spondyloarthritis Lead to Significantly Different Long-term Outcomes : A Cluster-based Analysis of the DESIR Cohort
Background/Purpose: AxSpA is a heterogeneous disease, leading to different treatment and follow-up modalities depending on the presentation, along with other elements (socio-economic, gender, etc..). In a…Abstract Number: 1094 • ACR Convergence 2020
Long Term Open Label Extension of Study of Tofacitinib in Refractory Dermatomyositis
Background/Purpose: Tofacitinib is a pan-JAK inhibitor that demonstrated safety and efficacy in a 12 week open label trial of 10 subjects with refractory dermatomyositis (NCT03002649).…Abstract Number: 1874 • ACR Convergence 2020
Differences Between Men and Women in the Patient Pathways to Diagnosis of Ankylosing Spondylitis
Background/Purpose: Healthcare claims databases can be used to identify patients with ankylosing spondylitis (AS) prior to diagnosis. This study explores differences in pathways to AS…Abstract Number: 1160 • ACR Convergence 2020
Treatment Intensity and Impact on Bone Lesion Evolution and Distribution Patterns in Severe Chronic Recurrent Multifocal Osteomyelitis
Background/Purpose: To compare bone lesion evolution and bone lesion distribution patterns identified by whole body magnetic resonance imaging (WB-MRI) by treatment intensity in patients with…Abstract Number: 1938 • ACR Convergence 2020
Risk for Vision Loss and Relapse in Patients with Giant Cell Arteritis
Background/Purpose: Giant cell arteritis (GCA) involves both the cranial and large vessels. Studies have shown that while the vision loss rates are higher, the relapse…Abstract Number: 1298 • ACR Convergence 2020
Lupus Damage Free-Survival by Age at Diagnosis: A Retrospective Incident Lupus Cohort
Background/Purpose: While medical comorbidities increase with age, younger age at onset of Systemic Lupus Erythematosus (SLE) has been associated with greater risk of some types…Abstract Number: 1983 • ACR Convergence 2020
Trajectories of Disease Activity in Patients with Newly Diagnosed Juvenile Idiopathic Arthritis in the Childhood Arthritis and Rheumatology Research Alliance Registry
Background/Purpose: To describe data-derived 2-year trajectories of disease activity in patients with recently diagnosed juvenile idiopathic arthritis (JIA) as measured by the clinical Juvenile Arthritis…Abstract Number: 1299 • ACR Convergence 2020
Longitudinal Patterns of Anxiety Symptomology Among Patients with Systemic Lupus Erythematosus (SLE) Remain Stable over Time and Do Not Associate with SLE Disease Activity
Background/Purpose: Almost 40% of patients with SLE have comorbid mental health conditions.1 Though depression is most commonly reported (24% to 30%), many SLE patients also…Abstract Number: 1312 • ACR Convergence 2020
Time-dependent Analysis of Incident Extra-articular Manifestations and Comorbidities in Axial Spondyloarthritis
Background/Purpose: Axial spondyloarthritis (axSpA) patients have higher morbidity and mortality compared to healthy controls. Much of this excess disease burden is related to extra-articular manifestations…Abstract Number: 1354 • ACR Convergence 2020
The Effect of 8 Years of TNF-α Blocking Therapy on Bone Mineral Density in Patients with Ankylosing Spondylitis
Background/Purpose: Ankylosing spondylitis (AS) is a chronic inflammatory disease that mainly affects the axial skeleton. Bone loss reflected by low bone mineral density (BMD) is…Abstract Number: 0272 • ACR Convergence 2020
Superior Discrimination Between LLDAS and DORIS Remission with Modification of Prednisolone Dose Threshold
Background/Purpose: Treat-to-target (T2T) approaches to rheumatic disease require the definition and validation of low disease activity and remission endpoints that should be concentrically more stringent.…Abstract Number: 1451 • ACR Convergence 2020
Longitudinal Assessment of Anti-beta 2 Glycoprotein in SLE
Background/Purpose: Although anti-beta2 glycoprotein is one of the three antiphospholipid antibodies recognized in the Sydney APS classification criteria, it is one of the least studied. …Abstract Number: 120 • 2020 Pediatric Rheumatology Symposium
Characteristics of the New Childhood Arthritis and Rheumatology Research Alliance Registry of Juvenile Myositis Patients Enrolled in the First Two Years
Background/Purpose: The New CARRA Registry of Juvenile Myositis (JM) was developed in 2017 to collect 10-year longitudinal data to increase knowledge of the course of…Abstract Number: 139 • 2020 Pediatric Rheumatology Symposium
Ongoing Disease Activity in Juvenile Idiopathic Arthritis (JIA) 18 Years After Disease Onset: A Population-based Nordic Study
Background/Purpose: Previously, we showed that ILAR JIA categories defined at disease onset change considerably during the first 8 years of disease course. Whether achieved remission…Abstract Number: 188 • 2019 ACR/ARP Annual Meeting
The Importance of Diagnosis: Clinical Distinctions Between Adult JIA and RA, and a Characterization of Patients with JIA Reclassified as RA in Adulthood
Background/Purpose: Upon transitioning from pediatric to adult care, many patients with JIA are labeled as having RA, despite the two diagnoses being distinct in care…
- « Previous Page
 - 1
 - …
 - 10
 - 11
 - 12
 - 13
 - 14
 - …
 - 20
 - Next Page »
 
